Suppression of bile acid synthesis as a tipping point in the disease course of primary sclerosing cholangitis

Suppression of bile acid synthesis as a tipping point in the disease course of primary sclerosing cholangitis

Background & Aims: Farnesoid X receptor (FXR) agonists and fibroblast growth factor 19 (FGF19) analogues suppress bile acid synthesis and are being investigated for their potential therapeutic efficacy in cholestatic liver diseases. We investigated whether bile acid synthesis associated with...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Peder Rustøen Braadland, Kai Markus Schneider, Annika Bergquist, Antonio Molinaro, Anita Lövgren-Sandblom, Marcus Henricsson, Tom Hemming Karlsen, Mette Vesterhus, Christian Trautwein, Johannes Roksund Hov, Hanns-Ulrich Marschall
Aineistotyyppi: Artikkeli
Kieli:English
Julkaistu: Elsevier 2022-11-01
Sarja:JHEP Reports
Aiheet:
Cholestasis
Ursodeoxycholic acid
Liver transplantation
Liver transplantation-free survival
Cholestatic liver disease
7α-Hydroxy-4-cholesten-3-one
Linkit:http://www.sciencedirect.com/science/article/pii/S2589555922001331

Internet

http://www.sciencedirect.com/science/article/pii/S2589555922001331

Samankaltaisia teoksia